The current financial score of Boston Scientific Corp is 8.30. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.44B, representing a year-over-year increase of 7.53%, while its net profit experienced a year-over-year increase of 13.80%.
The current valuation score of Boston Scientific Corp is 9.32. Its current P/E ratio is 18.51, which is 497.02% below the recent high of 110.52 and 6.58% above the recent low of 17.29.
The current earnings forecast score of Boston Scientific Corp is 8.06. The average price target is 62.27, with a high of 118.00 and a low of 44.00.
The current price momentum score of Boston Scientific Corp is 3.27. Currently, the stock price is trading between the resistance level at 46.58 and the support level at 41.91, making it suitable for range-bound swing trading.
The current institutional shareholding score of Boston Scientific Corp is 10.00. The latest institutional shareholding proportion is 94.35%, representing a quarter-over-quarter decrease of 0.00%.
The current risk assessment score of Boston Scientific Corp is 6.90. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.